Huntington's Disease Trial, Recruiting NCT04012411 Sponsor: University Hospital, Montpellier Condition: Huntington's Disease
Back to Huntingtons Disease

Huntington's Disease Trial, Recruiting

NCT04012411
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For patients:

  • You are 18 years old or older
  • You have national health insurance coverage
  • You have been diagnosed with Huntington's disease, confirmed by a genetic test showing 35 or more CAG repeats in the HTT gene
  • You are able and willing to give written consent to take part
  • If the study involves a lumbar puncture (a procedure to collect fluid from your spine), you are willing to agree to this

For healthy/control participants:

  • You have previously had a lumbar puncture for a medical reason and consented to samples being stored in a specific brain research sample bank called "Neuro"
  • Samples from that bank are available for you (2 mL blood, 0.5 mL plasma, and 0.5 mL cerebrospinal fluid)
  • You have been informed about the purpose of this sample bank and have not objected to it
  • You are within 5 years of age of a patient participant in the study

Who may not be able to join:

For all participants:

  • You are under legal protection (for example, under guardianship) (confirm with trial site)

For patients:

  • Your Huntington's disease is at an advanced stage that could affect your ability to complete thinking/memory tests or a brain scan
  • You have a medical reason that means you cannot have a brain MRI scan
  • If the study involves a lumbar puncture, you have a medical reason that means you cannot have one
  • You are not able to give informed consent yourself

For control participants:

  • You have a neurodegenerative disease (such as Parkinson's or Alzheimer's) or an inflammatory condition affecting the brain or spinal cord

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33(0)467336029

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
3 March 2020
Est. completion
1 September 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

BDNF(csf) in HD subjects compared to age-matched control subjects (+/- 5 years)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov